We are live on ! Find out more
NRSNW icon

NeuroSense Therapeutics Warrant
NRSNW

3 hedge funds and large institutions have $32.8K invested in NeuroSense Therapeutics Warrant in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 3 → 3 (0)

42% less capital invested

Capital invested by funds: $56.7K → $32.8K (-$23.9K)

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
EAM
1
Empery Asset Management
New York
$20.1K – – –
CS
2
Clear Street
New York
$12.7K – – –
UBS Group
3
UBS Group
Switzerland
$64 – – –

NRSNW Hedge Fund Activity: Q1 2026 in Review

3 of the 8,141 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q1 2026, worth a combined $32.8K — down 42% from $56.7K a quarter earlier.

Fund positioning in NRSNW was balanced in Q1 2026: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 3 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q1 2026, unchanged from Q4 2025.
  • Funds reported $32.8K of NeuroSense Therapeutics Warrant stock for Q1 2026, down 42% quarter-over-quarter.
  • 0 funds opened new NeuroSense Therapeutics Warrant positions in Q1 2026 and 0 closed out.

Based on aggregated 13F filings for Q1 2026.